Right ventricular (RV) dysfunction is a key determinant of outcomes in pulmonary hypertension and is increasingly recognized in other conditions, including heart failure with preserved ejection fraction, congenital heart disease, cardiomyopathies, acute infection, critical illness, and after left ventricular assist device implantation.
Therapeutic strategies are increasingly shifting toward RV–targeted approaches, such as modulation of inflammation, fibrosis, metabolism, and RV-pulmonary artery (PA) uncoupling coupling, highlighting the need for RV–specific endpoints in clinical trials.
✍🏼
@PullamsettiL @sbonnet2 @RRVdpool @Viniciodjperez
📷 Mechanisms driving right ventricular dysfunction in pulmonary hypertension.